Navegando por Palavras-chave "ulcerative colitis"
Agora exibindo 1 - 3 de 3
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAnti-neutrophil cytoplasmic antibodies in Brazilian patients with inflammatory bowel disease(H G E Update Medical Publishing S A, 2003-03-01) Cabral, Virginia Lucia Ribeiro [UNIFESP]; Miszputen, Sender Jankiel [UNIFESP]; Catapani, Wilson Roberto [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Background/Aims: Anti-neutrophil cytoplasmic antibody has been observed in the sera of patients with inflammatory bowel disease, but its prevalence depends on the population being studied and the method employed for its detection.Methodology: We evaluated the prevalence of anti-neutrophil cytoplasmic antibody by immunofluorescence assay in a series of Brazilian patients with inflammatory bowel disease: 40 patients with ulcerative colitis and 36 with Crohn's disease. We also correlated the presence of this antibody with duration of symptoms, site of the disease and inflammatory activity. Thirty healthy individuals comprised the control group.Results: Anti-neutrophil cytoplasmic antibody was detected in 27.5% of the patients with ulcerative colitis, and in 14.3% of those with Crohn's colitis. Perinuclear staining pattern was the most common, but atypical and nuclear patterns were also observed. There was no correlation between the presence of this antibody and any of the studied clinical variables No patient of the control group presented positive test.Conclusions: A positive anti-neutrophil cytoplasmic antibody test would not be helpful in the differential diagnosis between ulcerative colitis and Crohn's Colitis, since it has a moderate specificity of 86% for ulcerative colitis patients.
- ItemSomente MetadadadosEfeito da suplementação de cálcio e vitamina d nos marcadores bioquímicos de remodelação óssea e homeostase mineral em crianças e adolescentes com doenças inflamatórias intestinais em remissão(Universidade Federal de São Paulo (UNIFESP), 2014-05-28) Andrade, Jalousie Pedro de [UNIFESP]; Sdepanian, Vera Lucia Sdepanian [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objective: To evaluate the effect of calcium and vitamin D supplementation on biochemical markers of bone remodeling and mineral homeostasis in children and adolescents with quiescent Inflammatory Bowel Diseases. Methods: Eighteen patients, all male, with average age of 15.2 (2.9) years, diagnosed with quiescent Crohn?s Disease or Ulcerative Colitis with ileocolonic involvement and pancolitis and z-score of lumbar spine Bone Mineral Density L1-L4 inferior to -1 were evaluated. Calcium intake was assessed and calcium carbonated and colicalciferol were supplemented, to reach age recommended values. On the baseline and after there months, the following were measured in serum: bone formation marker procollagen type I N terminal (P1NP), bone resorption marker C-terminal cross-linked telopeptide of type I collagen, 25 OHD, intact parathormone, ionized calcium, phosphorous, magnesium,alkaline phosphathase. Results: After three months of investigation, there was an increase on 25 OHD levels (p=0.002) and a reduction on P1NP levels (p=0.042). However, CTX levels were stable. In an analysis considering puberal stages, the reduction of P1NP levels happened only on stage 4-5. There was a negative correlation between age and P1NP levels (r= -0,60;p=0,008), positive correlation between P1NP and CTx on the beginning (r=0.60;p=0.009), and after three months (r=0.87;p<0.001). Conclusion: In sum, Calcium and Vitamin D supplementation on the three-month period, led to an increase on serum concentrations of 25OHD with no changes on the boné resorption marker level, but the levels of P1NP marker were lower after this period, negatively correlated with age.
- ItemSomente MetadadadosEffectiveness of Infliximab in Brazilian Children and Adolescents With Crohn Disease and Ulcerative Colitis According to Clinical Manifestations, Activity Indices of Inflammatory Bowel Disease, and Corticosteroid Use(Lippincott Williams & Wilkins, 2010-06-01) Tiemi, Juliana [UNIFESP]; Komati, Saito [UNIFESP]; Sdepanian, Vera Lucia [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objective: the objective of the study was to evaluate the response to infliximab in children and adolescents with Crohn disease and ulcerative colitis up to week 22.Patients and Methods: A total of 21 patients with inflammatory bowel disease (IBD) received 5 mg/kg of infliximab at weeks 0, 2, 6, and 14. the following parameters were evaluated: clinical manifestations; activity indices of IBD, including the Pediatric Crohn Disease Activity Index for Crohn disease, the Lightiger Colitis Activity Index and the Pediatric Ulcerative Colitis Activity Index for ulcerative colitis, and the modified Harvey-Bradshaw Index for Crohn disease and ulcerative colitis; and the reduction or suspension of corticosteroid use.Results: All of the patients had improvements in clinical manifestations after the first infusion of infliximab. At week 22, 18 of 21 (85.7%) patients were categorized as being in remission, 3 of 21 (14.3%) patients were categorized as having clinical improvement, and none of the patients were categorized as having no response. There was a statistically significant difference in all of the IBD activity indices at weeks 2, 6, 14, and 22 compared with time 0. the corticosteroid use was completely discontinued in 6 of 15 patients by week 22.Conclusions: Infliximab is effective in the treatment of Crohn disease and ulcerative colitis in children and adolescents up to week 22.